/images/ppid_59c68470-image-177875006327078273.webp)
/images/ppid_59c68470-image-177894753738448074.webp)
What is the story about?
Meghmani Organics Ltd reported a weak set of fourth-quarter earnings for FY26 on May 14, with profitability and operating performance coming under significant pressure during the quarter.
The company posted a net profit of ₹8 crore for the quarter, down 59.6% from ₹19.8 crore in the corresponding period last year. Revenue declined 14.3% year-on-year to ₹474.3 crore from ₹553.5 crore earlier.
Operating performance deteriorated sharply during the quarter. EBITDA fell 70% to ₹19.7 crore from ₹65.5 crore a year ago, while EBITDA margin contracted to 4.1% from 11.8% in the year-ago period.
Following the earnings announcement, shares of Meghmani Organics came under pressure on the NSE. The stock was trading 2.9% lower at ₹52.45 as of 2:21 PM.
Meghmani Organics operates in the chemicals sector and is engaged in the manufacturing of crop protection chemicals, pigments and basic chemical products catering to domestic as well as international markets.
Also Read: Akums Drugs Q4 profit declines, but EBITDA jumps 62%; declares special dividend
The sharp decline in margins indicates continued pressure on costs and operating profitability, even as the company navigates a challenging demand environment.
The company posted a net profit of ₹8 crore for the quarter, down 59.6% from ₹19.8 crore in the corresponding period last year. Revenue declined 14.3% year-on-year to ₹474.3 crore from ₹553.5 crore earlier.
Operating performance deteriorated sharply during the quarter. EBITDA fell 70% to ₹19.7 crore from ₹65.5 crore a year ago, while EBITDA margin contracted to 4.1% from 11.8% in the year-ago period.
Following the earnings announcement, shares of Meghmani Organics came under pressure on the NSE. The stock was trading 2.9% lower at ₹52.45 as of 2:21 PM.
Meghmani Organics operates in the chemicals sector and is engaged in the manufacturing of crop protection chemicals, pigments and basic chemical products catering to domestic as well as international markets.
Also Read: Akums Drugs Q4 profit declines, but EBITDA jumps 62%; declares special dividend
The sharp decline in margins indicates continued pressure on costs and operating profitability, even as the company navigates a challenging demand environment.
/images/ppid_a911dc6a-image-177894863870819602.webp)
/images/ppid_a911dc6a-image-177894866956536720.webp)
/images/ppid_a911dc6a-image-177894853185657820.webp)
/images/ppid_a911dc6a-image-177894856669552845.webp)